Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9458315 | 0.85 | PREP (0.48) | PREPHTR4PRMT5WDR77HDAC1 | |
| SCHEMBL7398258 | 0.82 | KMT2A (0.54) | PREPHTR4PRMT5WDR77HRH3 | |
| SCHEMBL10078783 | 0.81 | HTR4 (0.48) | PREPHTR4PRMT5WDR77HDAC1 | |
| SCHEMBL9078900 | 0.80 | CNR2 (0.50) | PREPHTR4PRMT5WDR77HDAC1 | |
| SCHEMBL9623178 | 0.77 | HTR4 (0.50) | PREPHTR4PRMT5WDR77HDAC1 | |
| SCHEMBL592213 | 0.77 | — | — | |
| SCHEMBL590888 | 0.76 | HTR1A (0.55) | CNR2KMT2ADRD2 | |
| SCHEMBL10288963 | 0.75 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL12903051 | 0.75 | PBRM1 (0.60) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL23162787 | 0.74 | ADAM17 (0.59) | PREPHTR4HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114891-B2 | 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof | COMENTIS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| EP-2217597-B1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS INC (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2217597-A1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS, INC. (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009046025-A1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-20090088418-A1 | 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | COMENTIS, INC. (US) | 2009-04-02 | — | — | US | claimed |
| CN-104193741-B | Quinuclidine-4-ylmethyl 1H-indole-3-carboxylic acid ester derivant as alpha 7 nicotinic acetylcholine receptor ligands | 阿尔法梅根有限责任公司 | 2016-08-24 | — | — | CN | disclosed |
| US-8114891-B2 | 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof | COMENTIS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114891-B2 | 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof | COMENTIS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114891-B2 | 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof | COMENTIS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2217597-B1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS INC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2217597-B1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS INC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2217597-A1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS, INC. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009046025-A1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046025-A1 | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090088418-A1 | 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | COMENTIS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088418-A1 | 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | COMENTIS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088418-A1 | 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | COMENTIS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088418-A1 | 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRNA7, CHRNA5, CHRNA4 | PREP 2293/4885HTR4 143/4885PRMT5 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.